Inspira Technologies Partners with Glo-Med for 531 ART Device Deployment in Gulf States

Ticker: IINNW · Form: 6-K · Filed: Jan 30, 2024 · CIK: 1837493

Inspira Technologies Oxy B.H.N. LTD 6-K Filing Summary
FieldDetail
CompanyInspira Technologies Oxy B.H.N. LTD (IINNW)
Form Type6-K
Filed DateJan 30, 2024
Risk Levelmedium
Pages1
Reading Time1 min
Sentimentbullish

Complexity: simple

Sentiment: bullish

Topics: strategic-agreement, international-expansion, medical-devices

TL;DR

**Inspira just landed a deal to deploy 531 ART devices in the Gulf States, big market expansion!**

AI Summary

Inspira Technologies Oxy B.H.N. Ltd. announced on January 30, 2024, a strategic agreement with Glo-Med to deploy 531 ART devices in the Gulf States. This partnership marks Inspira's entry into a new market, potentially expanding its revenue streams and global presence. For investors, this signifies a concrete step towards commercializing its medical technology and could lead to increased sales and market share, making the stock more attractive.

Why It Matters

This agreement opens a new market for Inspira Technologies, potentially boosting future revenue and demonstrating progress in commercializing its medical devices.

Risk Assessment

Risk Level: medium — While promising, the success of the deployment and market penetration in the Gulf States still carries execution risks and depends on regulatory approvals and adoption rates.

Analyst Insight

A smart investor would monitor the progress of the Glo-Med partnership and the actual deployment of the 531 ART devices, looking for updates on revenue generation and market penetration in the Gulf States, as this could signal significant growth potential.

Key Numbers

Key Players & Entities

Forward-Looking Statements

FAQ

What is the primary purpose of this 6-K filing by Inspira Technologies Oxy B.H.N. Ltd.?

The primary purpose of this 6-K filing is to report a press release issued on January 30, 2024, titled 'Inspira Technologies Signs Strategic Agreement to Enter Gulf States with Glo-Med for Deployment of 531 ART Devices,' which is furnished as Exhibit 99.1.

Which specific parts of the press release are incorporated by reference into Inspira Technologies' registration statements?

The first three paragraphs and the section titled 'Forward-Looking Statements' in the press release are incorporated by reference into the Registrant’s Registration Statements on Form F-3 (Registration No. 333-266748) and Form S-8 (Registration No. 333-259057).

Who signed this 6-K report on behalf of Inspira Technologies Oxy B.H.N. Ltd.?

The 6-K report was signed by Dagi Ben-Noon, the Chief Executive Officer of Inspira Technologies Oxy B.H.N. Ltd., on January 30, 2024.

What is the Commission File Number for Inspira Technologies Oxy B.H.N. Ltd.?

The Commission File Number for Inspira Technologies Oxy B.H.N. Ltd. is 001-40303.

What type of annual report does Inspira Technologies Oxy B.H.N. Ltd. file?

Inspira Technologies Oxy B.H.N. Ltd. indicates by check mark that it files annual reports under cover of Form 20-F.

Filing Stats: 304 words · 1 min read · ~1 pages · Grade level 8.8 · Accepted 2024-01-30 08:40:02

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Inspira Technologies Oxy B.H.N. Ltd. Date: January 30, 2024 By: /s/ Dagi Ben-Noon Name: Dagi Ben-Noon Title: Chief Executive Officer 2

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing